While this study makes significant strides in understanding the effects of FAK and RAF/MEK inhibition in melanoma models driven by mutant BRAF, it is possible that our findings may not represent the biology of all melanoma patients with brain metastases including those driven by mutant NRAS or loss of NF1. This evidence concerns the gene PTK2 and melanoma.